As FADS1 and FADS2 inhibition did not result in decreased HUFA incorporation into the TCA cycle as expected, we performed a global metabolomics analysis in primary relapsed patient AML cells to determine the metabolic effects of FADS inhibition. The gene discussed is FADS1; the disease is acute myeloid leukemia.